Emerging data suggest Retatru tide , a dual agonist targeting both incretin and GIP , may provide a significant step forward for body management . Initial clinical tests have demonstrated impressive decreases in abdominal tissue, conceivably surpassing existing obesity medications . However , further evaluation is needed to fully determine its sust